Lassa Fever Vaccine: Phase 1 clinical trial begins
by Press Release from Outbreak News Today on (#4TCZ4)
Themis Bioscience and CEPI - the Coalition for Epidemic Preparedness Innovations - announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis' vaccine candidate against Lassa fever. The MV-LASV Lassa fever vaccine candidate, is based on Themis' proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur. The MV-LASV ["]
The post Lassa Fever Vaccine: Phase 1 clinical trial begins appeared first on Outbreak News Today.